ANDA Filing Alone Is Not “Willful Infringement” Under Waxman/Hatch – Court
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Circuit reverses an award of attorneys’ fees for GlaxoSmithKline in Ceftin patent litigation. Apotex’ conduct in filing a cefuroxime ANDA did not rise to the level of an “exceptional” case, the court says.
You may also be interested in...
Generic Firms Must Pay Actos Legal Fees, Partly Because Of Claim Flip-Flops
In deciding for Takeda, judge says Mylan and Alphapharm also disregarded court orders and used faulty witnesses during their patent challenges.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.